Əsas səhifə

Çap

Əks əlaqə

İnfo
Topical lidocaine for the treatment of postherpetic neuralgia

Mündəricat

Topical lidocaine for the treatment of postherpetic neuralgia

Sübutlu məlumatların xülasələri
16.07.2017 • Sonuncu dəyişiklik 16.07.2017
Editors

Topical lidocaine appears to provide some benefit in the treatment of postherpetic neuralgia compared to placebo.

A Cochrane review [withdrawn from publication] included 3 studies with a total of 314 subjects. A meta-analysis combining two of the three studies identified a significant difference between the topical lidocaine and control groups for the primary outcome measure: a mean improvement in pain relief according to a pain relief scale. Topical lidocaine relieved pain better than placebo (P = 0.003). There was a statistical difference between the groups for the secondary outcome measure of mean VAS score reduction (P = 0.03), but this was only for a single small trial. There were a similar number of adverse skin reactions in both treatment and placebo groups.

Comment: The quality of evidence was downgraded by sparse data.

Ədəbiyyat

  1. Khaliq W, Alam S, Puri NK. WITHDRAWN: Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2013;(10):CD004846.